Novel Long-Acting Injection Cuts Schizophrenia Relapse

A long-acting subcutaneous antipsychotic (LASCA) suspension that combines risperidone with a novel copolymer substantially reduces both risk for relapse and time to impending relapse for patients with schizophrenia, new research suggests. In the phase 3 Risperidone Subcutaneous Extended-release (RISE) trial, which included more than 500 patients with schizophrenia, those who received the novel combination treatment, … Read more